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INTRODUCTION 
Cardiac action potential 
 The electrophysiologic behavior of the heart is determined by ordered propagation of 
excitatory stimuli that result in rapid depolarization and slow repolarization, thereby 
generating action potentials (AP) in myocytes, which reflect the sequental activation and 
inactivation of inward (Na
+
 and Ca
2+
) and outward (K
+
) currents carrying ion channels. 
The electrical cycle of the myocytes has been divided in five phases. When the excitation 
threshold is exceeded, cardiomyocytes are depolarized (phase 0) by a rapid inflow of Na
+
 
ions generating a large and fast inward Na
+
 current (INa). This current determines also the 
velocity of impulse propagation through the His-Purkinje system, working atrial and 
ventricular myocytes (’fast-channel tissues’). In sino-atrial and atrioventricular node 
mainly the Ca
2+
 current (ICa) is responsible for depolarization (’slow-channel tissues’). 
Phase 1 is the initial part of repolarization, mainly governed by the transient outward 
current (Ito). In phase 2, also named plateau, the late components of inward currents (late 
INa, late ICa) oppose the outward repolarizing currents i.e. the rapid and slow components 
(IKr and IKs) of the delayed rectifier K
+
 current and the inward rectifier K
+
 current (IK1). 
Phase 3 is the terminal part of repolarization, which differs from phase 2 for its faster 
repolarization rate, the outward gradually overcome the inward currents, enabling 
fast repolarization of the action potential. The loss of one repolarizing current may not lead 
to excessive AP lengthening, since other unimpaired K
+
 channels may provide sufficient 
repolarizing capacity, i.e. there is a redundancy of the repolarization process 
(‘repolarization reserve’). The key players of the reserve are IKr, IKs, IK1, and presumably 
Ito [2-5]. Phase 4 describes membrane potential during diastole. Time-independent (or 
background) currents may also contribute to the whole action potential course i.e. the 
Na
+
/K
+
 pump current (INaK), the Na
+
/Ca
2+
 exchanger current (INCX) and the ATP-sensitive 
poatssium current (IK(ATP)).  In the sino-atrial node heart rate is regulated by spontaneous 
electrical pacemaker activity mainly controlled by the If current. This current determines 
the slope of diastolic depolarization and cardiac frequency, and its inhibition causes heart 
rate reduction. The ´funny´ (If) current is so termed because of its unusual characteristics, 
including that of being an inward current that is activated on hyperpolarization and not on 
depolarization like other known currents. 
Antiarrhythmic drugs 
Most antiarrhythmic agents are traditionally grouped according to Vaughan Williams 
classification based on their dominant electrophysiological action. Class I antiarrhythmic 
agents have a blockade of the fast-inward sodium channel on myocardium. Class II agents 
are antisympathetic drugs, particularly the β-adrenoceptor blockers. Class III drugs act 
through delaying repolarization of cardiac myocytes and thus cause a lengthening of action 
potential duration (potassium-channel blockers). Class IV antiarrhythmic drugs are the 
calcium channel blockers and class V drugs are specific bradycardic agents. 
Class I antiarrhythmic drugs 
These compounds share the ability to block the fast Na
+
 channels responsible for the 
upstroke and rapid conduction of the cardiac action potential. In the ECG, this effect may 
be reflected as widening of the P wave, widening of the QRS complex, prolongation of the 
PR interval, or a combination. They are capable not only of slowing but blocking 
intracardiac conduction and induce arrhythmias. This phenomenon has become widely 
recognized, and has led to reduction in the usage of these agents. Class I antiarrhythmic 
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drugs usually exert post-repolarization refractoriness, when the refractory period extends 
well beyond phase 3, even after complete repolarization. Class I drugs are subdivided 
based on the kinetics of the Na
+
 channel effects, that determine the heart rates at which 
their electrophysiologic effects become manifest.  
i. Class I/A drugs have intermediate kinetics, their fast-channel tissue conduction 
slowing effects may or may not be evident on an ECG obtained during normal rhythm at 
normal rates. Class I/A drugs block repolarizing K
+
 channels also, prolonging the 
repolarization and refractory periods (the interval from the beginning of the AP until the 
fiber is able to conduct another AP) of fast-channel tissues. On the ECG, this effect is 
reflected as QT-interval prolongation even at normal rates. 
ii. Class I/B drugs have fast kinetics, they express their electrophysiologic effects 
only at fast heart rates. Thus, an ECG obtained during normal rhythm at normal rates 
usually shows no evidence of fast-channel tissue conduction slowing.  
iii. Class I/C drugs have slow kinetics, they express their electrophysiologic effects at 
all heart rates. Thus, an ECG obtained during normal rhythm at normal heart rates usually 
shows fast-channel tissue conduction slowing. Class I/B drugs and class I/C drugs do not 
block K
+
 channels directly. 
Class I drugs can be useful in supraventricular and ventricular tachyarrhythmias 
also, but they are not generally recommended for patients with structural heart disorder. 
The Cardiac Arrhythmia Suppression Trial (CAST) showed that flecainide and 
encainide, two Class I/C sodium channel blocker antiarrhythmic drugs, increased mortality 
rates compared with placebo due to proarrhythmic effects. Consequently, the interest of 
drug development for treatment of ventricular tachycardia (VT) and atrial fibrillation (AF) 
has been shifted toward those agents that prevent and terminate re-entrant arrhythmias by 
prolonging the action potential duration.  
Class II antiarrhythmic drugs  
Class II drugs are β-blockers. These agents have been given many names in the 
literature (beta-adrenoceptor blockers, b-adrenergic–blocking agents, b-adrenergic 
antagonists, b-antagonists, b-adrenergic receptor antagonists). They are particularly used 
not only for the management of cardiac arrhythmias, but hypertension, angina pectoris, 
congestive heart failure, essential tremor, glaucoma, migraine prophylaxis and myocardial 
infarction.
 
As antiarrhythmic agents they suppress beta-adrenergic signaling in the heart by 
competitively inhibiting agonist binding to beta-adrenergic receptors. They are useful in 
preventing sudden death due to ventricular tachyarrhythmias associated with acute 
myocardial ischemia, congenital long QT syndrome, and congestive heart failure. They are 
also quite valuable in controlling the ventricular rate in patients with atrial fibrillation. β-
blockers affect predominantly slow-channel tissues (SA and AV nodes), where they 
decrease rate of automaticity and slow conduction velocity. Thus, heart rate is slowed and 
the PR interval is lengthened on the ECG.  
Class II drugs are used primarily to treat supraventricular tachycardias (SVT), 
including sinus tachycardia, AV nodal reentry, atrial fibrillation, and atrial flutter. These 
drugs are also used to treat VTs to raise the threshold for ventricular fibrillation (VF) and 
reduce the ventricular proarrhythmic effects of β-adrenoceptor stimulation.  
Class III antiarrhythmic drugs 
Class III antiarrhythmic action, i.e. lengthening of cardiac action potential duration 
(APD), is usually caused by blockade of one or more potassium channels. A great number 
of non-cardiac drugs cause lengthening of APD in both ventricular muscle cells and 
Purkinje fibres by using a similar mode of action. The drugs act also in slow- and fast-
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channel tissues. Because repolarization and refractoriness are prolonged, rate of 
automaticity is reduced. QT-interval prolongation is the predominant effect on the ECG. 
These drugs are used to treat supraventricular and ventricular arrhythmias. Class III drugs 
have a risk of proarrhythmia, particularly torsades de pointes ventricular tachycardia. 
Class IV antiarrhythmic drugs 
Class IV drugs are the nondihydropyridine Ca channel blockers, which depress Ca-
dependent action potentials in slow-channel tissues and thus decrease the rate of 
automaticity, slow conduction velocity, and prolong refractoriness. Heart rate is slowed, 
the PR interval is lengthened, and the AV node transmits rapid atrial depolarizations at a 
lower frequency. These drugs are used primarily to treat supraventricular tachycardias or 
tachyarrhythmias. 
Class V antiarrhythmic drugs 
Class V drugs are specific bradycardic agents with sino-atrial pacemaker current (If) 
inhibitory property. If plays an important role in spontaneous diastolic depolarization. The 
current flows through hyperpolarization-activated cyclic nucleotide-gated (HCN) channels. 
Block of the pacemaker currrent reduces the steepness of diastolic depolarization. Thus, 
heart rate is slowed and the RR interval is lengthened on the ECG.  
Medical treatment of angina pectoris 
Stable angina is a form of coronary artery disease. A multifaceted approach is 
required in the management of angina. It includes lifestyle intervention, medical arsenal 
and revascularization therapy. The current pharmacological treatment of stable angina 
pectoris is based on beta adrenoceptor blockers, calcium channel antagonists, nitrates (and 
related derivatives). Number of patients have contraindications or remain unrelieved from 
anginal discomfort and have relative intolerances to maximum doses of traditional 
antianginal agents. ß-blockers and many calcium channel blockers have similar depressive 
hemodynamic and significant electrophysiological effects. Therefore antianginal drugs 
without serious limitations are needed. New classes of treatments (ivabradine, ranolazine) 
with entirely different mechanisms of action have now been added. 
Beta blockers 
Heart rate has a prominent role in the development and pathophysiology of 
myocardial ischaemia. In patients with coronary artery disease, ischaemic episodes could 
be generated by an elevation in heart rate that elicits imbalance between myocardial 
oxygen supply and demand. The antiischemic effect of beta blockers is attributable, at least 
in part, to heart rate reduction and that is regarded as an important therapeutic target in 
preventing ischaemia by reducing myocardial oxygen consumption. Beta blockers apart 
from the numerous, proven, valuable effects in the treatment of cardiovascular diseases 
(angina pectoris, arrhythmias, myocardial infarction, heart failure) have several side effects 
including bronchospasm, atrioventricular block, lassitude, sleep disturbance, depression, 
change in lipid status, sexual dysfunction, possible increase in blood sugar level, rebound 
phenomena. The hemodynamic effects might be also limiting factors at application e.g. the 
negative inotropic effect. Furthermore beta blockers (except carvedilol and nebivolol) may 
be contraindicated in patients with peripheral vascular disease. In ST-segment elevation 
myocardial infarction (STEMI) early i.v. use of beta blockers is clearly contraindicated in 
patients with clinical signs of hypotension or congestive heart failure. In the absence of 
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contraindications, beta-blockers remain the reference treatment to prevent angina attacks, 
particularly after myocardial infarction. 
Calcium channel blockers 
Calcium channel blockers reduce calcium influx into the cell, producing dual 
vasodilating and negative inotropic effects, which respectively vary depending on the 
different compounds. Dihydropyridines (amlodipine, felodipine, isradipine, nicardipine 
and nifedipine) mostly have a peripheral vasodilating action and could increase heart rate. 
Usually they must be associated with a beta-blocker or, failing this, with an alternative 
cardiac slowing agent (e.g. ivabradine). The non-dihydropyridines (diltiazem and 
verapamil) both have a peripheral vasodilating action and probradycardic and myocardial 
depressant effects. The hemodynamic effects might be also limiting factors at application 
(the considerable blood pressure lowering property or the negative inotropic effect). In 
patients with angina pectoris the most common coexisting cardiovascular risk factor is 
hypertension and, therefore, dihydropyridines or other calcium channel blockers (diltiazem 
or verapamil) have a role in combined treatment with or as a substitute for beta blockers. 
Nitrates 
Nitrates are indirect nitric oxide donors, which block calcium entry in smooth muscle 
cells and promote their relaxation through production of cyclic guanosine monophosphate 
(cGMP). Their main haemodynamic effect is to reduce preload by venodilatation, although 
at high doses they have an arterial vasodilating effect, causing dilatation of the epicardial 
arteries. Nitrates are usually well tolerated, although they may cause headaches, restricting 
their use. Because of their vasodilating action, they increase heart rate and it is 
recommended to combine them with preventative treatments such as beta-blockers, 
ivabradine or calcium channel blockers, which have a heart rate-lowering effect. 
Ranolazine 
Ranolazine (Ranexa
®
) is a novel antianginal agent (a piperazine derivative) shown to 
exert anti-ischemic effects without causing significant bradycardia or hypotension. The 
drug reduces ischemia via inhibition of the late phase of the inward sodium current (late 
INa) during cardiac repolarization, with a consequent reduction in intracellular sodium and 
calcium overload which could contribute to its therapeutic effect. The drug was approved 
in 2006 in the US for use in management of chronic angina pectoris. Ranolazine is useful 
in patients who have not achieved an adequate response with other antianginal 
medications, and is used in combination with amlodipine, ß-blockers, or nitrates.  
In addition, ranolazine has been proposed to possess antiarrhythmic potential which 
was principally related to the inhibition of sodium current (INa), rapid delayed rectifier 
potassium current (IKr) and calcium current (ICa). A suppression of ventricular tachycardias 
by ranolazine after non-ST-segment elevation myocardial infarction has been proven in the 
MERLIN-TIMI 36 trial. Experimental models and clinical reports have revealed an 
antiarrhythmic potential of ranolazine also in long QT syndrome. Ranolazine has been 
associated with good safety profile during clinical usage. The side-effects are mild and 
tolerable (e.g. dizziness, nausea, constipation, headache). 
Ivabradine 
Ivabradine (Procoralan
®
) is the only clinically available selective heart rate reducing 
agent and it exerts anti-ischaemic effects in patients with chronic stable angina. Ivabradine 
inhibits the pacemaker (If) current in the heart with reasonable selectivity and with minimal 
effect on haemodynamic parameters. According to the BEAUTIFUL (morBidity-mortality 
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EvAlUaTion of the If inhibitor ivabradine in patients with coronary disease and left 
ventricULar dysfunction) study, ivabradine can be used to reduce the incidence of 
coronary artery disease outcomes in a subgroup of patients who have heart rates of 70 bpm 
or greater. Ivabradine has been associated with a good safety profile during its clinical 
development. In a trial, mild, tolerable visual symptoms (e.g. abrupt changes in light 
intensity) were reported as side effects. Ivabradine is beneficial in patients with chronic 
stable angina pectoris equally to beta receptor blocker and calcium channel antagonist 
drugs. Contrary to several heart rate-reducing drugs, ivabradine lowers heart rate both at 
rest and during exercise without producing any negative inotropic or vasoconstrictor effect. 
The results of the recent SHIFT study support the significance of heart-rate reduction with 
ivabradine for improvement of clinical outcomes in heart failure and confirm the important 
role of heart rate in the pathophysiology of this disorder. Improvement of regional 
myocardial blood flow and function and reduction of infarct size by ivabradine have also 
been described.  
This selective heart rate reducing agent, lacking the negative inotropic effect, may 
offer a new therapeutic perspective in the treatment of ischaemic heart diseases e.g. in 
stable angina pectoris, particularly in patients with left ventricular dysfunction. Based on 
the recent clinical trials and experiments, widening the indication of ivabradine for the 
treatment of heart failure or myocardial infarction is expected. 
Aims of the study 
The primary goal of the present study was to investigate in detail the cellular 
electrophysiological effects of ranolazine and ivabradine in dog and human heart 
preparations using conventional microelectrode technique. The effects of the drugs were 
mainly investigated in dog, a species resembling human in heart size, spontaneous 
frequency and repolarization. 
RESULTS 
Effects of ranolazine on transmembrane action potentials 
Dog Purkinje fibre 
Ranolazine (dose- and rate-dependently) decreased the maximum rate of rise of the 
action potential upstroke (Vmax) in isolated dog cardiac Purkinje fibres. Action potential 
duration measured at 50% and 90% of repolarization (APD50, APD90) was shortened in a 
concentration-dependent manner at pacing with a constant cycle length of 500 ms. The 
reduction of APD50 was more pronounced than that of APD90 which resulted in an action 
potential with a triangular shape. The depression of Vmax evoked by ranolazine was 
strongly dependent upon stimulation frequency (“use-dependency”); i.e., as pacing cycle 
length was decreased, the depression of Vmax was increased. The block was statistically 
significant only at stimulation rates faster or equal of 2 Hz. 
Dog papillary muscle 
In dog right ventricular papillary muscle at a stimulation cycle length of 1000 ms 
ranolazine exerted no statistically significant effect on action potential duration. 
Ranolazine decreased the Vmax and increased the impulse conduction time (CT) dose- and 
rate-dependently. This effect was significant also at the concentration of 5 µM at basic 
cycle length of 300-500 ms. The decrease in Vmax was more pronounced in case of 
elevating extracellular potassium concentration from 4 to 6 mM and produced a shift in the 
normalized Vmax-membrane potential curve to more negative potentials. 
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Human papillary muscle 
In human right ventricular papillary muscle ranolazine moderately shortened the 
APD in 2 out of 4 experiments at a stimulation cycle length of 1000 ms. On average 
ranolazine exerted no statistically significant effect on APD. Ranolazine dose- and rate-
dependently decreased the Vmax. In human preparations pronounced biphasic effect was 
evident during the incubation, i.e. first shortening (faster development of late sodium 
channel block) and later prolongation of APD (formation of IKr block) was detected 
suggesting multiple ion channel block with different drug binding kinetics. 
Onset and offset kinetics of Vmax block 
In dog papillary muscles, after 1 minute of rest, train of stimuli driven at the cycle 
length of 400 ms, the onset kinetics of 20 µM ranolazine induced Vmax block was fitted by 
a single exponential, resulting in the onset rate kinetic constant of τ = 3.5 ± 0.8 beat-1. At 
the same stimulation cycle length of 400 ms, the recovery of Vmax (offset kinetics) during 
control was best fit to a single exponential relation. The time constant for recovery of Vmax 
during control was fast (τfast = 35.7 ± 5.4 ms) and before final repolarization of the basic 
action potential, it was almost complete. In the presence of 20 μM ranolazine the recovery 
kinetics of Vmax was best fitted with a two exponential relation. In addition to a fast 
component (τfast = 29.1 ± 2.9 ms) which reflects recovery of the drug-free sodium channels, 
a slow component (τslow = 1.58 ± 0.25 s) of recovery of Vmax was revealed following 
exposure to ranolazine. This second slow component for recovery of Vmax may reflect 
effects on drug-affected sodium channels.  
Dog midmyocardial preparations 
In dog midmyocardial tissue (M-cells) 10 µM ranolazine exerted no significant effect 
on APD at basic cycle length of 1000 ms, however, at higher concentration (20 µM) it 
produced a slight prolongation of APD. In these preparations ranolazine decreased the 
maximum rate of rise of the action potential upstroke (Vmax) which was significant only in 
higher concentration (20 µM) at basic cycle length of 1000 ms. 
Dispersion of repolarization 
In dog heart ranolazine decreased the dispersion of repolarization i.e. the difference 
in APD90 values between Purkinje fibres and papillary muscles. The drug produced 
abbreviation in APD of Purkinje fibre and at the same time exerted no significant effect on 
the subendocardial layers (papillary muscle). 
Dog atria 
In atria from dog in sinus rhythm (SR) a statistically significant prolongation of the 
APD was observed in the presence of 10 µM ranolazine and this lengthening further 
increased at 20 µM. In addition, the drug exerted a marked and significant use-dependent 
depression of Vmax at basic cycle length of 300-700 ms. This block was significantly more 
expressed in atria than in ventricle at fast stimulation frequencies (BCL= 300-400 ms). In 
tachypacing induced remodelled dog atrial preparations ranolazine also produced 
statistically significant prolongation of APD90 with a concomittant shortening of APD50. 
The repolarization (APD90) lengthening and Vmax blocking effects were more pronounced 
in normal (healthy) atria (SR), than in remodelled atria (AF). 
9 
Effects of ivabradine on transmembrane action potentials 
Dog Purkinje fibre 
In dog Purkinje strands, stimulation was terminated to allow development of 
spontaneous activity. The developed spontaneous frequency in the control preparations 
was 0.47 ± 0.06 Hz. Ivabradine concentration-dependently decreased the steepness of 
spontaneous diastolic depolarization and slowed spontaneous rate of firing of the Purkinje 
fibres. Spontaneous activity was completely abolished by 10 μM ivabradine in all 
preparations. In isolated dog Purkinje fibres ivabradine concentration- and rate-
dependently decreased the maximum rate of rise of the action potential upstroke (Vmax), 
and action potential amplitude while action potential duration measured at 50% of 
repolarization was shortened in a concentration-dependent manner at pacing with a 
constant cycle length of 500 ms. The depression of Vmax evoked by 1 and 10 μM 
ivabradine was strongly dependent upon stimulation frequency (“use-dependent”); i.e., as 
pacing cycle length was decreased, the depression of Vmax was increased.  
Dog papillary muscle  
In dog right ventricular papillary muscle at a stimulation cycle length of 1000 ms 
ivabradine lengthened the action potential repolarization in a concentration dependent 
manner. Ivabradine decreased the Vmax and increased the impulse conduction time (CT) 
dose- and rate-dependently.  
The drug moderately prolonged the APD in case of normal repolarization reserve, 
while after attenuation of the repolarization reserve by inhibition of the inward rectifier 
potassium current by adding 30 μM BaCl2 it further lengthened the ventricular 
repolarization. 
Human papillary muscle  
In human ventricular muscle preparations at a stimulation cycle length of 1000 ms 
1 μM ivabradine did not change ventricular repolarization and a small, but significant 
prolongation of the action potential repolarization was observed only in the presence of 
high (10 μM) concentration of ivabradine. Ivabradine dose- and rate-dependently 
decreased the Vmax and increased the impulse conduction time.  
Onset and offset kinetics of Vmax block  
In dog ventricular muscles driven at the cycle length of 400 ms the onset kinetics of 
Vmax block induced by 10 μM ivabradine was fitted to a single exponential, resulting in the 
onset rate kinetic constant of τ = 13.9 ± 3.2 beat−1. In dog ventricular muscles at the 
stimulation cycle length of 400 ms, the recovery of Vmax during control was best fit to a 
single exponential relation. The time constant for recovery of Vmax during control was fast 
(τfast= 46.2 ± 4.3 ms) and before final repolarization of the basic action potential, it was 
almost complete. In the presence of 10 μM ivabradine the recovery kinetics of Vmax was 
best fit with a twoexponential relation. In addition to a fast component (τfast= 41.2 ± 8.2 
ms) which reflects recovery of the drug-free sodium channels, a slow component (τslow= 
8.76 ± 1.34 s) of recovery of Vmax was revealed following exposure to ivabradine. This 
second slow component for recovery of Vmax may reflect effects on drug-affected sodium 
channels.  
Dispersion of repolarization 
In dog heart ivabradine preserved the dispersion of repolarization i.e. the difference 
in APD90 values between Purkinje fibres and papillary muscles at basic cycle length of 
10 
1000 ms. The drug produced prolongation in APD of Purkinje fibre and exerted the same 
effect on the subendocardial layers (papillary muscle). 
DISCUSSION 
Major findings 
In this thesis several effects of novel antianginal drugs on transmembrane action 
potentials are summarized. The effects of ranolazine and ivabradine were mainly 
investigated in dog, a species resembling human in heart size, spontaneous frequency and 
repolarization. The results led us to the conclusion that ranolazine and ivabradine at 
relatively high concentrations in dog and human cardiac preparations produce a 
concentration- and frequency-dependent depression of Vmax and able to prolong action 
potential duration i.e. exerts Class I and III antiarrhythmic actions. Ranolazine produces 
depression of Vmax with rather fast onset and offset kinetics, i.e. exerts Class I/B 
antiarrhythmic action (similar to that of mexiletine) not only in normal and remodelled 
atria, but also in the ventricle. Other important finding is that due to its multiple ion 
channel blocking property, ranolazine alters the repolarization in a complex manner in 
remodelled atria. Ivabradine (at high concentrations) can be considered as a Na
+
 channel 
blocker antiarrhythmic drug with slow kinetic onset and recovery i.e. exerts Class I/C 
antiarrhythmic action (similar to that of flecainide or propafenone). Ranolazine and 
ivabradine are devoid from the effect to increase the dispersion of repolarization between 
Purkinje fibres and the subendocardial muscle layers. 
Class I antiarrhythmic action      
The dose- and frequency dependent Vmax block (induced by ranolazine and 
ivabradine) could be attributed to the inhibition of the fast/peak Na
+
 current. Vmax 
measurements are indicative for INa function, but they cannot be used for quantitative 
estimation of sodium channel availability, since it could be underestimated. It was 
demonstrated that Vmax could be regarded as a nonlinear indicator of the fast inward 
sodium current.  
Vmax block in the ventricle 
The Vmax block of ranolazine was similar in frequency-dependent characteristic than 
that of class I/B antiarrhythmic drugs (e.g. mexiletine). In previous studies the drug was 
reported to produce atrial-predominant sodium channel block and postrepolarization 
refractoriness which was postulated in the mechanism of suppressing atrial fibrillation. The 
investigators did not apply properly wide range of stimulation frequencies (BCL= 300-
5000 ms) in the presence of ranolazine at therapeutically meaningful concentration using 
the conventional microelectrode technique. Therefore the effect of ranolazine on peak INa 
and conduction in the ventricle might have been underestimated and neglected. In a 
previous study the investigators found that ranolazine blocked peak INa with high IC50 
values (at 1, 2 and 5 Hz were 260, 157 and 154 µM, respectively) in HEK293 cells using 
whole-cell patch-clamp technique at room temperature which is about one order of 
magnitude higher than our results based on Vmax measurements and should be extrapolated 
with caution to intact heart including humans. Fredj et al. found preferential ranolazine 
block of sustained vs peak Na
+
 channel current for LQT-3 mutant channels (IC50= 15 vs 
135 µM) also in HEK293 cells using patch-clamp technique at room temperature which 
ratio in our experiments - in ’healthy’ cardiac preparations at 37C - is almost 1:1. The 
effects of ranolazine on onset and offset kinetics of Vmax indicate that ranolazine kinetically 
resembles fast/intermediate (Class I/B) antiarrhythmic agents. Similar results were 
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described by others earlier at high concentration using different protocol to determine 
unbinding kinetics.  
The effects of ivabradine on recovery of Vmax observed in dog ventricular muscle 
indicate that ivabradine resembles kinetically slow antiarrhythmic agents. Frequency-
dependent Vmax block has been demonstrated previously only in small animals at high 
concentration (50 μM) of ivabradine. The possible decrease of INa by ivabradine may 
contribute to the inhibition of the pacemaker function.  
The sodium current determines greatly the velocity of impulse propagation through 
the His-Purkinje system, working atrial and ventricular cardiac tissue. Since ranolazine and 
ivabradine produced significant depression of Vmax at fast stimulation frequencies, it can 
therefore be expected that the drugs may suppress the impulse conduction at fast heart rate 
i.e. during tachycardia or that extrasystoles with short coupling interval during cardiac 
arrhythmias.  
Vmax block in atria vs. ventricle 
The less negative resting potential, the greater density of sodium channels and the 
more negative half-inactivation voltage in atrial myocytes could make the sodium channel 
block more vigorous. We investigated the possible difference in Vmax block between atria 
and ventricle in the example of ranolazine, since this drug was reported to produce atrial-
predominant use dependent block of sodium channels and postrepolarization refractoriness 
which was postulated in the mechanism of suppressing atrial fibrillation. Similarly to that 
described by others earlier the decrease in Vmax was more pronounced in the atria than in 
the ventricle. However, in our experiments the Vmax block and consequently the CT were 
also substantial (at fast stimulation frequencies) in ventricular preparations.  
Vmax block in normal vs. remodelled atria 
Since it has been suggested that ranolazine application could be effective in atrial 
fibrillation, we investigated the possible difference in Vmax block between normal and 
remodelled atria in the example of ranolazine. Remodelled atrial preparations were 
obtained from tachypacing induced remodelled dog herats (used as an established model 
for mimicing the pathological tissue in atrial fibrillation). The frequency dependent Vmax 
block was less pronounced in remodelled than in normal atria. This is in accordance with a 
previous study in which reduced peak INa density was detected in AF. The less pronounced 
effect on Vmax by ranolazine in remodelled atrial tissue can be explained by shorter 
repolarization and, as a consequence, longer diastolic intervals allowing more recovery at 
each cycle. In AF the use-dependent Na
+
 channel block by ranolazine most likely enhances 
postrepolarization refractoriness in addition to the repolarization lengthening in the 
remodelled atria. Despite the prolongation in the APD90, ranolazine decreased the APD50 
value in remodelled atria, which may reflect inhibitory effect on late INa. The latter current 
was recently reported to be upregulated in isolated human atrial myocytes obtained from 
AF patients in experiments with patch-clamp technique.  
Vmax block in case of elevated extracellular potassium concentration 
Block of sodium current has been demonstrated to be more pronounced when the 
resting membrane potential is partly depolarized e.g. in ischemic tissues. We investigated 
this phenomenon in the example of ranolazine induced Vmax block in case of normal (4 
mM) and elevated (6 mM) extracellular potassium concentration. Depression of Vmax and 
conduction were more pronounced in case of elevated potassium concentration, e.g. when 
the resting membrane potential is partly depolarized, even as in the presence of an 
ischaemic cardiac substrate.  
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It can therefore be expected that the drugs may suppress the impulse conduction at 
fast heart rate i.e. during tachycardia or that extrasystoles with short coupling interval 
during cardiac arrhythmias in patients with angina pectoris.  
Class III antiarrhythmic action 
The repolarization lengthening effect of ranolazine and ivabradine could be best 
explained by the drug evoked IKr block. In various cardiac preparations, the effect of 
ranolazine and ivabradine on APD depends on the different density of various ion channels 
(late INa, late ICa, IKr, IKs) and the extent of blocking effects of the compounds on these 
channels. The antiarrhythmic efficacy of most pure class III drugs is compromised by their 
inherent property to induce excessive lengthening of the action potential (reverse 
frequency dependence) and their inability to prolong the action potential when most 
needed, namely during tachycardia. Overall, an ideal antiarrhythmic agent does not exist, 
and drug selection should be highly individualized. In case of ranolazine and ivabradine 
the additional sodium channel block would limit action potential prolongation at slow rate 
due to the IKr inhibition. 
Ranolazine has been shown to cause a slight prolongation of the QT interval on the 
ECG. In dog midmyocardial preparations ranolazine (20 µM) produced prolongation of 
repolarization in accordance with the previous (clinical) observation. Ivabradin exerted 
significant prolongation of repolarization in human preparations only at higher 
concentration (10 μM). 
Attenuated repolarization reserve 
Remodelling, pharmacological modulation or genetic channelophathies of certain 
potassium channels, which normally contribute to repolarization, can attenuate the 
capability of the heart to repolarize. In these situations inhibition of other potassium 
channels may lead to unexpectedly augmented APD prolongation, resulting in 
proarrhythmic reactions.  In previous studies the investigators found that ivabradine at 3 
and 10 μM prolongs repolarization in guinea-pig papillary muscles. Our results support the 
action potential lengthening effect of ivabardine also in dog and human cardiac 
preparations especially in case of attenuated repolarization reserve.  
Class V antiarrhythmic action 
Ivabradine is originally a class V antiarrhytmic agent with antianginal property, since 
the drug exerts well-known If blocking effect. Ivabradine induces (a marked exponential 
use-dependent) blockade of the hyperpolarization activated If current with relatively high 
(2.8 μM) IC50 in rabbit sinus node cells. Ivabradine concentration-dependently decreased 
the steepness of spontaneous diastolic depolarization and slowed spontaneous rate of firing 
of the Purkinje fibres which effect could be best explained by the drug evoked If block. 
This ability on Purkinje fibres might be considered as an antiarrhythmic property and 
might suppress the initiation of arrhythmias. Ranolazine does not exert class V 
antiarrhythmic action. 
Dispersion of ventricular repolarization 
In Purkinje fibres, where the late INa is robust, ranolazine and ivabradine produced 
shortening of APD50. This impact on the plateau slope might be related to the inhibitory 
effect of the drugs on the persistent,‘window’ (late INa) current. Block of this Na
+
 current 
might also have an additional therapeutic value and would also limit action potential 
prolongation at slow rate due to the IKr inhibition of the drugs at higher concentration. 
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Owing to this ’dirty’ (mixed) characteristic, ranolazine and ivabradine are devoid from the 
effect to increase the dispersion of repolarization between Purkinje fibres and the 
subendocardial muscle layers, oppositely in case of ’pure’ class III drugs. This ability can 
be considered as an advantageous property. Excessive shortening of the Purkinje fibre 
APD may increase the risk of reentry, but in the case of ranolazine and ivabradine the 
mentioned IKr blocking effect and the postrepolarization refractoriness (due to the sodium 
channel blockade) attenuate this potential risk factor also.  
Human cardiac tissue 
To our knowledge our results were the first in which the effects of ranolazine and 
ivabradine were investigated in human ventricular muscle preparations with conventional 
microelectrode technique. We observed depression of the Vmax to similar extent as in dog 
papillary muscles. Ivabradine at 10 μM exerted significant effect on action potential 
duration also in human ventricular preparations. Our results suggest that late INa has less 
contribution to repolarization in dog than in human ventricular preparations. In case of 
ranolazine APD50 values were shortened in human but not in dog ventricular muscle. In 
this context it should be noted that biphasic time dependent changes were observed 
(especially in human preparations) with ranolazine, i.e. the APD shortening effect always 
preceded the drug evoked tendency to repolarization lengthening. The initial shortening of 
APD was much greater in human than in dog, which may also indicate, that late INa has 
less contribution to repolarization in dog.  
Therapeutically relevant concentrations of the drugs 
The therapeutically relevant concentration of ranolazine and ivabradine should be 
interpreted with great caution. For example in previous studies the authors interpreted 2-10 
µM ranolazine as therapeutically relevant concentration, but they did not provide a cross 
reference to a factual effective plasma level. Authors report steady state through levels at a 
therapeutic dose in man to be 464 ng/ml. This equates to a plasma concentration of 1 
micromolar. Thus the doses used in our study may 5- to 20-fold higher than therapeutic 
concentration according to this article.  
In case of ivabradine though therapeutic plasma concentrations are about 0.04–0.07 
μM, the drug has been tested at higher (0.17 μM) concentration in healthy volunteers. 
Other investigators interpreted 3 µM ivabradine as „clinically relevant” concentration. 
Therefore the (0.1–1–10 μM) concentrations applied in our experiments may be relevant, 
since the tissue concentration can be expected to be higher than that of the plasma, in 
accordance with the high volume of distribution (close to 100 L) value of the drug. In this 
context, the relatively low therapeutic plasma concentration might be the result of possibly 
meaningful tissue appearance of ivabradine. We did not find significant effect of 0.1 μM 
ivabradine on Vmax and APD measurements. 
Clinical implications 
It has to be emphasized that the drugs so far have proved to be safe and free from any 
proarrhythmic events in clinical trials. The sodium channel blocking ability on Purkinje 
fibres might be considered as an antiarrhythmic property and might suppress the initiation 
of an extrasystole, limit any repolarization lengthening and most importantly, it could 
decrease dispersion of repolarization. Since ranolazine and ivabradine produced significant 
depression of Vmax at fast stimulation frequencies, it can therefore be expected that the 
drugs may suppress the impulse conduction at fast heart rate i.e. during tachycardia or that 
extrasystoles with short coupling interval during cardiac arrhythmias. However the 
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possible contribution of this effect to the clinical benefit of the drug is still unclear. The 
properties of ranolazine resemble that of chronically administered amiodarone and may 
represent antiarrhythmic property. Amiodarone has minimal proarrhythmic risk, but has 
numerous noncardiac toxicities that require frequent monitoring. Clinical findings support 
the suggestion that ranolazine might be efficacious not only in supraventricular but also in 
ventricular arrhythmias. Although proarrhythmic side effects do not seem to be a major 
concern during ranolazine and ivabradine application, they can not be completely ruled out 
in some pathological conditions, e.g. in case of drug accumulation or intoxication, or in 
case of attenuated repolarization reserve like in heart failure, diabetes or in long QT 
syndromes. Therefore, further studies with ranolazine and ivabradine are needed to 
determine its safety and efficacy in future clinical use. 
CONCLUSIONS 
Based on the cellular cardiac electrophysiological properties of ranolazine and 
ivabradine it can be concluded that these antianginal drugs also exert Class I and III 
antiarrhythmic properties (at higher concentrations) which can be advantageous in the 
treatment of patients with ischemic heart disease, heart failure liable to disturbances of 
cardiac rhythm. Ranolazine decreases (and ivabradine does not increase) the dispersion of 
ventricular repolarization (the difference in APD90 values between Purkinje fibres and 
papillary muscles), which can contribute to the antiarrhythmic property of the drugs. 
Ranolazine exerts amiodaron-like antiarrhythmic properties, without serious side-effects. 
Ivabradine is beneficial in patients with angina pectoris equally to beta receptor blockers 
without producing any negative inotropic or vasoconstrictor effect. Based on the recent 
clinical trials and experiments, widening the indication of the drugs is expected (heart 
failure and atrial fibrillation for ranolazine; myocardial infarction and heart failure for 
ivabradine).  
These ‘dirty’ drugs combine several modes of antiarrhythmic actions which might be 
the key to find a drug that has powerful antiarrhythmic potential with lack of 
proarrhythmic side effects. 
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